UNSPSC 51292912: Mianserin

This classification denotes a serotonin antagonist and antidepressant agent and adrenergic antagonist with the molecular formula C18H20N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 250PJI13LM, chemically known as 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine but generally known as mianserin, which bears US NIH Compound Identifier 4184. European Medicines Agency schedules Mianserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08939MIG.

UNSPSC 51292912 Mianserin is a Commodity code that in practice captures pharmaceutical procurement by state and local agencies, though recent activity shows the code is being applied to a broader range of drug products and pharmacy services than the specific active pharmaceutical ingredient (mianserin) its name suggests. State and local governments use this code to solicit naloxone and drug deactivation systems for public health initiatives, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing vehicles, and direct-to-manufacturer pharmacy benefit arrangements. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing organizations serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance). The mix reflects demand across community health programs, state Medicaid and employee health plans, and multi-jurisdictional procurement consortia.

Recent activity spans Florida, Texas, and Minnesota-based cooperative arrangements serving multiple states including Oregon. Representative opportunities include Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford, Florida (response deadline July 26, 2026); the Texas Health and Human Services Commission's April 2026 Request for Information seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's January 2026 RFP for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities with proposals due March 26, 2026, and resulting contracts effective July 1, 2026. All three solicitations emphasize compliance with federal drug supply chain security and Good Manufacturing Practice requirements, and the Minnesota cooperative contract requires vendor insurance coverage including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability per occurrence.